{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:43:08Z","timestamp":1762875788931},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,6,21]],"date-time":"2016-06-21T00:00:00Z","timestamp":1466467200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s12328-016-0657-4","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:41:35Z","timestamp":1466642495000},"page":"252-256","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?"],"prefix":"10.1007","volume":"9","author":[{"given":"Kazuhiko","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiji","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisaku","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"key":"657_CR1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","volume":"2","author":"JH Kao","year":"2002","unstructured":"Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395\u2013403.","journal-title":"Lancet Infect Dis"},{"key":"657_CR2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212\u20139.","journal-title":"Vaccine"},{"key":"657_CR3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem D, Prince AM. Hepatitis B virus infection\u2014natural history and clinical consequences. N Engl J Med. 2004;350:1118\u201311129.","journal-title":"N Engl J Med"},{"key":"657_CR4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","volume":"344","author":"I Dervite","year":"2001","unstructured":"Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68\u20139.","journal-title":"N Engl J Med"},{"key":"657_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","volume":"68","author":"JR Wands","year":"1975","unstructured":"Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105\u201312.","journal-title":"Gastroenterology"},{"key":"657_CR6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(75)90897-1","volume":"2","author":"RM Galbraith","year":"1975","unstructured":"Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975;2:528\u201330.","journal-title":"Lancet"},{"key":"657_CR7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/cid\/civ474","volume":"61","author":"JM Collins","year":"2015","unstructured":"Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304\u20136.","journal-title":"Clin Infect Dis"},{"key":"657_CR8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/hepr.12578","volume":"46","author":"H Takayama","year":"2016","unstructured":"Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus\/hepatitis C virus co-infection. Hepatol Res. 2016;46:489\u201391.","journal-title":"Hepatol Res"},{"key":"657_CR9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742\u20138.","journal-title":"Hepatology"},{"key":"657_CR10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515\u201323.","journal-title":"Lancet"},{"key":"657_CR11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932\u201354.","journal-title":"Hepatology"},{"key":"657_CR12","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1086\/590968","volume":"47","author":"T Umemura","year":"2008","unstructured":"Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52\u20136.","journal-title":"Clin Infect Dis"},{"key":"657_CR13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12072-011-9279-6","volume":"7","author":"CJ Liu","year":"2013","unstructured":"Liu CJ, Chen PJ, Chen DS, et al. Hepatitis B virus reactivation post-cancer chemotherapy: pathogenesis and management. Hepatol Int. 2013;7:316\u201326.","journal-title":"Hepatol Int"},{"key":"657_CR14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719\u201329.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"657_CR15","doi-asserted-by":"crossref","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9(11):e112647.","journal-title":"PLoS One"},{"key":"657_CR16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/gutjnl-2011-300832","volume":"61","author":"Y Tamada","year":"2012","unstructured":"Tamada Y, Yatsuhashi H, Masaki N, et al. Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut. 2012;61:765\u201373.","journal-title":"Gut"},{"key":"657_CR17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jmv.20411","volume":"77","author":"H Yotsuyanagi","year":"2005","unstructured":"Yotsuyanagi H, Okuse C, Yasuda K, et al. Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol. 2005;77:39\u201346.","journal-title":"J Med Virol"},{"key":"657_CR18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/jmv.20824","volume":"79","author":"K Hayashi","year":"2007","unstructured":"Hayashi K, Katano Y, Takeda Y, et al. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J Med Virol. 2007;79:366\u201373.","journal-title":"J Med Virol"},{"key":"657_CR19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.27604","volume":"61","author":"R Salpini","year":"2015","unstructured":"Salpini R, Colagrossi L, Bellocchi MC, et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2015;61:823\u201333.","journal-title":"Hepatology"},{"key":"657_CR20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.virol.2015.06.017","volume":"484","author":"P Colson","year":"2015","unstructured":"Colson P, Borentain P, Coso D, et al. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology. 2015;484:354\u201363.","journal-title":"Virology"},{"key":"657_CR21","doi-asserted-by":"crossref","unstructured":"Hayashi K, Ishigami M, Ishizu Y, et al. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. J Gastroenterol. 2016 [Epub ahead of print].","DOI":"10.1007\/s00535-016-1187-z"},{"key":"657_CR22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","volume":"57","author":"A Kramvis","year":"2014","unstructured":"Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57:141\u201350.","journal-title":"Intervirology"},{"key":"657_CR23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jmv.24115","volume":"87","author":"H Kamitsukasa","year":"2015","unstructured":"Kamitsukasa H, Iri M, Tanaka A, et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol. 2015;87:589\u2013600.","journal-title":"J Med Virol"},{"key":"657_CR24","doi-asserted-by":"crossref","unstructured":"Mochida S, Nakao M, Nakayama N, et al. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol. 2016 [Epub ahead of print].","DOI":"10.1007\/s00535-016-1168-2"},{"key":"657_CR25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jcv.2005.10.006","volume":"35","author":"E Sagnelli","year":"2006","unstructured":"Sagnelli E, Coppola N, Marrocco C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: areciprocal viral interaction. J Clin Virol. 2006;35:317\u201320.","journal-title":"J Clin Virol"},{"key":"657_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcv.2016.02.026","volume":"78","author":"A Monte De","year":"2016","unstructured":"De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27\u201330.","journal-title":"J Clin Virol"},{"key":"657_CR27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27922","volume":"62","author":"V Saxena","year":"2015","unstructured":"Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715\u201325.","journal-title":"Hepatology"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-016-0657-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-016-0657-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-016-0657-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T19:06:55Z","timestamp":1600801615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-016-0657-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,21]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1007\/s12328-016-0657-4","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,21]]}}}